Lumosa invited to 2017 STAIR X

Lumosa was invited to the tenth Stroke Treatment Academic Industry Roundtable (STAIR X) held on October 23-24 in Washington D.C., USA, where top scientists and specialists gather to publish the latest research on cerebral stroke. Applications of neuroprotection agents on acute ischemic stroke were discussed during the STAIR conference. Neuroprotectants may protect the brain from ischemia and can be combined with thrombectomy to extend the "Golden Hour" and enhance treatment effect. Lumosa's LT3001 possess thrombolytic and neuroprotective functions and is currently under Phase 1 trial in the US.

Media exposure by GlobalData

Media exposure by GlobalData

Lumosa partners with Camargo for LT1001

Lumosa Therapeutics Partners with Camargo Pharmaceutical Services in the Development of Naldebain(R) in the US

USFDA approved the phase 1 trial for LT3001

Lumosa Therapeutics Co., Ltd., (TPEx: 6535, hereinafter 'Lumosa') is pleased to announce that its lead drug candidate for acute ischemic stroke, LT3001, has received approval from the US FDA to begin Phase I clinical trials. The first clinical trial is a double-blinded dose escalating study in healthy volunteers and expected to be completed in the first half of 2018.

Lumosa's LT1001 approved by Taiwan FDA

Lumosa Therapeutics Co., Ltd. (Lumosa, 6535.TWO) announced the approval of LT1001, a long-acting analgesic injection (product name: Naldebain®) by Taiwan Food and Drug Administration (TFDA) today (March 6, 2017).  Naldebain®, soon to be launched in Taiwan, is 100% "made in Taiwan"; from concept through product development, clinical trials, and dossier compilation. 

Lumosa scientist spoke at 2017 International Stroke Conference

Lumosa Therapeutics Co., Ltd. (Lumosa, 6535.TWO) announced the preclinical study results of its drug candidate for the treatment of acute ischemic stroke at the International Stroke Conference 2017 (ISC).